Panic Disorder With AgoraphobiaNCT04793828
A Transdiagnostic, Self-guided Internet Intervention ("Velibra") for Waitlist Patients With Anxiety Disorders
A study testing Velibra in people with Panic Disorder With Agoraphobia and Panic Disorder Without Agoraphobia, run by Charite University, Berlin, Germany at 1 site in Germany.
Trial summary
The project's aim is to investigate the effect of a transdiagnostic, self-guided, internet-based cognitive behavioral therapy program in waitlist patients with anxiety disorders. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Panic Disorder With Agoraphobia, Panic Disorder Without Agoraphobia, Generalized Anxiety Disorder
- What is being tested?
- Velibra
- Type of treatment
- Lifestyle or therapy programme
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 30 participants
- Where
- 1 siteGermany
- Study dates
- 4 Jul 2020to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Diagnosis of panic disorder with or without agoraphobia, social anxiety disorder, or generalized anxiety disorder
- Knowledge of German that is sufficient for engaging with the treatment and responding to the questionnaires
- Written informed consent
- Internet access
Who cannot join
- Diagnoses of severe mental comorbidities (e.g., schizophrenia, severe major depression, borderline personality disorder)
- Acute suicidality
- Started or changed anxiolytic pharmacotherapy recently (currently or in the past four weeks)
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Germany1 site, 1 recruiting
- Recruiting
Department of Psychiatry and Psychotherapy, Charité Campus Mitte - Universitätsmedizin Berlin
Berlin, 10117
Anna Wehrheim, M.Sc.-Psych., anna.wehrheim@charite.de
Lena Pyrkosch, Dipl.-Psych., +49 30 450 517 214, lena.pyrkosch@charite.de
About this study
Official title: The Effect of a Transdiagnostic, Self-guided Internet Intervention ("Velibra") for Waitlist Patients With Anxiety Disorders
The project's aim is to investigate the effect of a transdiagnostic, self-guided, internet-based cognitive behavioral therapy program in waitlist patients with anxiety disorders.
Read the detailed description
Patients who fulfill the inclusion criteria and are interested in psychotherapy are offered participation in the study to bridge the waiting time for face-to-face psychotherapy. After obtaining informed consent, a pre-treatment assessment is conducted. Then, participants are provided access to velibra, an internet-based cognitive behavioral therapy program which they can work through at their own pace. While velibra is a self-guided program, participants are supported by study personnel during four assessments at four time points: pre-treatment, mid-treatment (after the first three velibra modules), post-treatment and at the one-month follow-up. The investigators expect improvements on the primary as well as the secondary outcomes. Furthermore, the investigators are interested in studying the acceptability of velibra and whether positive changes already become observable after the first three modules, i.e., at the mid-treatment assessment.
- Conditions
- Panic Disorder With Agoraphobia, Panic Disorder Without Agoraphobia, Generalized Anxiety Disorder, Social Anxiety Disorder
- Being tested
- Velibra
- Keywords
- cognitive behavioral therapy, internet intervention, administrative-supported, anxiety, panic disorder, social anxiety disorder, generalized anxiety disorder, computerized CBT, anxiety disorders, velibra, psychotherapy
- Medical subject headings
- Generalized Anxiety Disorder, Phobia, Social, Anxiety Disorders, Panic Disorder
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
VelibraBehavioural
Velibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content.
| Study group | Role | What they receive |
|---|---|---|
| Intervention (velibra) | Experimental | Arm consisting of participants who receive velibra, an internet-based cognitive behavioral therapy program. Receives: Behavioral: Velibra |
What is being measured
The primary outcome is the main question the study is designed to answer.
Panic and Agoraphobia Scale (PAS)
The Panic and Agoraphobia Scale (PAS) is a self-report questionnaire used to measure the symptom severity of panic disorder with or without agoraphobia. It is given to study participants diagnosed with panic disorder with or without agoraphobia. Total score values range from 0 to 52, with higher scores indicating a worse outcome.
Measured: Baseline (pre-treatment)
Panic and Agoraphobia Scale (PAS)
The Panic and Agoraphobia Scale (PAS) is a self-report questionnaire used to measure the symptom severity of panic disorder with or without agoraphobia. It is given to study participants diagnosed with panic disorder with or without agoraphobia. Total score values range from 0 to 52, with higher scores indicating a worse outcome.
Measured: During the intervention (mid-treatment)
Panic and Agoraphobia Scale (PAS)
The Panic and Agoraphobia Scale (PAS) is a self-report questionnaire used to measure the symptom severity of panic disorder with or without agoraphobia. It is given to study participants diagnosed with panic disorder with or without agoraphobia. Total score values range from 0 to 52, with higher scores indicating a worse outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
Panic and Agoraphobia Scale (PAS)
The Panic and Agoraphobia Scale (PAS) is a self-report questionnaire used to measure the symptom severity of panic disorder with or without agoraphobia. It is given to study participants diagnosed with panic disorder with or without agoraphobia. Total score values range from 0 to 52, with higher scores indicating a worse outcome.
Measured: 1-month follow-up
Liebowitz Social Anxiety Scale (LSAS)
The Liebowitz Social Anxiety Scale (LSAS) is a self-report questionnaire used to measure the symptom severity of social anxiety disorder. It is given to study participants diagnosed with social anxiety disorder. Total score values range from 0 to 72, with higher scores indicating a worse outcome.
Measured: Baseline (pre-treatment)
Liebowitz Social Anxiety Scale (LSAS)
The Liebowitz Social Anxiety Scale (LSAS) is a self-report questionnaire used to measure the symptom severity of social anxiety disorder. It is given to study participants diagnosed with social anxiety disorder. Total score values range from 0 to 72, with higher scores indicating a worse outcome.
Measured: During the intervention (mid-treatment)
Liebowitz Social Anxiety Scale (LSAS)
The Liebowitz Social Anxiety Scale (LSAS) is a self-report questionnaire used to measure the symptom severity of social anxiety disorder. It is given to study participants diagnosed with social anxiety disorder. Total score values range from 0 to 72, with higher scores indicating a worse outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
Liebowitz Social Anxiety Scale (LSAS)
The Liebowitz Social Anxiety Scale (LSAS) is a self-report questionnaire used to measure the symptom severity of social anxiety disorder. It is given to study participants diagnosed with social anxiety disorder. Total score values range from 0 to 72, with higher scores indicating a worse outcome.
Measured: 1-month follow-up
Penn State Worry Questionnaire (PSWQ)
The Penn State Worry Questionnaire (PSWQ) is a self-report questionnaire used to measure the symptom severity of generalized anxiety disorder It is given to study participants diagnosed with generalized anxiety disorder. Total score values range from 16 to 80, with higher scores indicating a worse outcome.
Measured: Baseline (pre-treatment)
Penn State Worry Questionnaire (PSWQ)
The Penn State Worry Questionnaire (PSWQ) is a self-report questionnaire used to measure the symptom severity of generalized anxiety disorder It is given to study participants diagnosed with generalized anxiety disorder. Total score values range from 16 to 80, with higher scores indicating a worse outcome.
Measured: During the intervention (mid-treatment)
Penn State Worry Questionnaire (PSWQ)
The Penn State Worry Questionnaire (PSWQ) is a self-report questionnaire used to measure the symptom severity of generalized anxiety disorder It is given to study participants diagnosed with generalized anxiety disorder. Total score values range from 16 to 80, with higher scores indicating a worse outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
Penn State Worry Questionnaire (PSWQ)
The Penn State Worry Questionnaire (PSWQ) is a self-report questionnaire used to measure the symptom severity of generalized anxiety disorder It is given to study participants diagnosed with generalized anxiety disorder. Total score values range from 16 to 80, with higher scores indicating a worse outcome.
Measured: 1-month follow-up
Secondary outcomes (28)
Beck Anxiety Inventory (BAI)
The Beck Anxiety Inventory (BAI) is a self-report questionnaire used to measure the symptom severity of anxiety in general. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 63, with higher scores indicating a worse outcome.
Measured: Baseline (pre-treatment)
Beck Anxiety Inventory (BAI)
The Beck Anxiety Inventory (BAI) is a self-report questionnaire used to measure the symptom severity of anxiety in general. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 63, with higher scores indicating a worse outcome.
Measured: During the intervention (mid-treatment)
Beck Anxiety Inventory (BAI)
The Beck Anxiety Inventory (BAI) is a self-report questionnaire used to measure the symptom severity of anxiety in general. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 63, with higher scores indicating a worse outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
Beck Anxiety Inventory (BAI)
The Beck Anxiety Inventory (BAI) is a self-report questionnaire used to measure the symptom severity of anxiety in general. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 63, with higher scores indicating a worse outcome.
Measured: 1-month follow-up
Beck Depression Inventory-II (BDI-II)
The Beck Depression Inventory-II (BDI-II) is a self-report questionnaire used to measure the symptom severity of depression. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 63, with higher scores indicating a worse outcome.
Measured: Baseline (pre-treatment)
Beck Depression Inventory-II (BDI-II)
The Beck Depression Inventory-II (BDI-II) is a self-report questionnaire used to measure the symptom severity of depression. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 63, with higher scores indicating a worse outcome.
Measured: During the intervention (mid-treatment)
Beck Depression Inventory-II (BDI-II)
The Beck Depression Inventory-II (BDI-II) is a self-report questionnaire used to measure the symptom severity of depression. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 63, with higher scores indicating a worse outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
Beck Depression Inventory-II (BDI-II)
The Beck Depression Inventory-II (BDI-II) is a self-report questionnaire used to measure the symptom severity of depression. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 63, with higher scores indicating a worse outcome.
Measured: 1-month follow-up
Anxiety Sensitivity Index (ASI)
The Anxiety Sensitivity Index (ASI) is a self-report questionnaire used to measure anxiety sensitivity. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 64, with higher scores indicating a worse outcome.
Measured: Baseline (pre-treatment)
Anxiety Sensitivity Index (ASI)
The Anxiety Sensitivity Index (ASI) is a self-report questionnaire used to measure anxiety sensitivity. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 64, with higher scores indicating a worse outcome.
Measured: During the intervention (mid-treatment)
Anxiety Sensitivity Index (ASI)
The Anxiety Sensitivity Index (ASI) is a self-report questionnaire used to measure anxiety sensitivity. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 64, with higher scores indicating a worse outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
Anxiety Sensitivity Index (ASI)
The Anxiety Sensitivity Index (ASI) is a self-report questionnaire used to measure anxiety sensitivity. It is given to all study participants regardless of diagnosis. Total score values range from 0 to 64, with higher scores indicating a worse outcome.
Measured: 1-month follow-up
ICD-10-Symptom-Rating (ISR)
The ICD-10-Symptom-Rating (ISR) is a self-report questionnaire used to measure mental distress related to syndromes defined in the ICD-10. It is given to all study participants regardless of diagnosis. Total score values (based on subscale means) range from 0 to 4, with higher scores indicating a worse outcome.
Measured: Baseline (pre-treatment)
ICD-10-Symptom-Rating (ISR)
The ICD-10-Symptom-Rating (ISR) is a self-report questionnaire used to measure mental distress related to syndromes defined in the ICD-10. It is given to all study participants regardless of diagnosis. Total score values (based on subscale means) range from 0 to 4, with higher scores indicating a worse outcome.
Measured: During the intervention (mid-treatment)
ICD-10-Symptom-Rating (ISR)
The ICD-10-Symptom-Rating (ISR) is a self-report questionnaire used to measure mental distress related to syndromes defined in the ICD-10. It is given to all study participants regardless of diagnosis. Total score values (based on subscale means) range from 0 to 4, with higher scores indicating a worse outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
ICD-10-Symptom-Rating (ISR)
The ICD-10-Symptom-Rating (ISR) is a self-report questionnaire used to measure mental distress related to syndromes defined in the ICD-10. It is given to all study participants regardless of diagnosis. Total score values (based on subscale means) range from 0 to 4, with higher scores indicating a worse outcome.
Measured: 1-month follow-up
Short-Form Health Survey (SF-12)
The Short-Form Health Survey (SF-12) is a self-report questionnaire used to measure health-related quality of life. It is given to all study participants regardless of diagnosis. Values of the summary scores range from 0 to 100, with higher scores indicating a better outcome.
Measured: Baseline (pre-treatment)
Short-Form Health Survey (SF-12)
The Short-Form Health Survey (SF-12) is a self-report questionnaire used to measure health-related quality of life. It is given to all study participants regardless of diagnosis. Values of the summary scores range from 0 to 100, with higher scores indicating a better outcome.
Measured: During the intervention (mid-treatment)
Short-Form Health Survey (SF-12)
The Short-Form Health Survey (SF-12) is a self-report questionnaire used to measure health-related quality of life. It is given to all study participants regardless of diagnosis. Values of the summary scores range from 0 to 100, with higher scores indicating a better outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
Short-Form Health Survey (SF-12)
The Short-Form Health Survey (SF-12) is a self-report questionnaire used to measure health-related quality of life. It is given to all study participants regardless of diagnosis. Values of the summary scores range from 0 to 100, with higher scores indicating a better outcome.
Measured: 1-month follow-up
General Self--Efficacy Scale (GES)
The General Self--Efficacy Scale (GES) is a self-report questionnaire used to measure self-efficacy. It is given to all study participants regardless of diagnosis. Total score values range from 10 to 40, with higher scores indicating a better outcome.
Measured: Baseline (pre-treatment)
General Self--Efficacy Scale (GES)
The General Self--Efficacy Scale (GES) is a self-report questionnaire used to measure self-efficacy. It is given to all study participants regardless of diagnosis. Total score values range from 10 to 40, with higher scores indicating a better outcome.
Measured: During the intervention (mid-treatment)
General Self--Efficacy Scale (GES)
The General Self--Efficacy Scale (GES) is a self-report questionnaire used to measure self-efficacy. It is given to all study participants regardless of diagnosis. Total score values range from 10 to 40, with higher scores indicating a better outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
General Self--Efficacy Scale (GES)
The General Self--Efficacy Scale (GES) is a self-report questionnaire used to measure self-efficacy. It is given to all study participants regardless of diagnosis. Total score values range from 10 to 40, with higher scores indicating a better outcome.
Measured: 1-month follow-up
Internal, Powerful Others, and Chance Questionnaire (IPC)
The Internal, Powerful Others, and Chance Questionnaire (IPC) is a self-report questionnaire used to measure locus of control. It is given to all study participants regardless of diagnosis. Score values of each of the three subscales range from 8 to 48, with higher scores on the subscale of internal orientation indicating a better outcome and higher scores on the subscales of powerful others orientation and chance orientation indicating a worse outcome.
Measured: Baseline (pre-treatment)
Internal, Powerful Others, and Chance Questionnaire (IPC)
The Internal, Powerful Others, and Chance Questionnaire (IPC) is a self-report questionnaire used to measure locus of control. It is given to all study participants regardless of diagnosis. Score values of each of the three subscales range from 8 to 48, with higher scores on the subscale of internal orientation indicating a better outcome and higher scores on the subscales of powerful others orientation and chance orientation indicating a worse outcome.
Measured: During the intervention (mid-treatment)
Internal, Powerful Others, and Chance Questionnaire (IPC)
The Internal, Powerful Others, and Chance Questionnaire (IPC) is a self-report questionnaire used to measure locus of control. It is given to all study participants regardless of diagnosis. Score values of each of the three subscales range from 8 to 48, with higher scores on the subscale of internal orientation indicating a better outcome and higher scores on the subscales of powerful others orientation and chance orientation indicating a worse outcome.
Measured: Immediately after / as soon as possible after the intervention (post-treatment)
Internal, Powerful Others, and Chance Questionnaire (IPC)
The Internal, Powerful Others, and Chance Questionnaire (IPC) is a self-report questionnaire used to measure locus of control. It is given to all study participants regardless of diagnosis. Score values of each of the three subscales range from 8 to 48, with higher scores on the subscale of internal orientation indicating a better outcome and higher scores on the subscales of powerful others orientation and chance orientation indicating a worse outcome.
Measured: 1-month follow-up
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Mar 2021
- Study start4 Jul 2020
- Primary completion31 Dec 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Panic Disorder With AgoraphobiaStudies of the same condition, open and under way.
- More trials run by Charite University, Berlin, GermanyThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Charite University, Berlin, Germany
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Anna Wehrheim, Charite University, Berlin, Germany
- Investigators
- Lena Pyrkosch, Dipl.-Psych., Principal investigator, Department of Psychiatry and Psychotherapy, Charité Campus Mitte - Universitätsmedizin BerlinAnna Wehrheim, M.Sc.-Psych., Principal investigator, Department of Psychiatry and Psychotherapy, Charité Campus Mitte - Universitätsmedizin Berlin
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04793828
- Sponsor's protocol ID
- EA 1/322/19
- Status last verified
- May 2026
- First submitted
- 22 Feb 2021
- Last updated
- 7 May 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 7 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Effect of a Transdiagnostic, Self-guided Internet Intervention ("Velibra") for Waitlist Patients With Anxiety Disorders
- ClinicalTrials.gov ID
- NCT04793828
- Acronym / sponsor ID
- EA 1/322/19
- Conditions
- Panic Disorder With Agoraphobia, Panic Disorder Without Agoraphobia, Generalized Anxiety Disorder, Social Anxiety Disorder
- Keywords
- cognitive behavioral therapy, internet intervention, administrative-supported, anxiety, panic disorder, social anxiety disorder, generalized anxiety disorder, computerized CBT
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Charite University, Berlin, GermanyUniversity, hospital or other
- Study start
- 4 Jul 2020 (actual)
- Primary completion
- 31 Dec 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 11 Mar 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The project's aim is to investigate the effect of a transdiagnostic, self-guided, internet-based cognitive behavioral therapy program in waitlist patients with anxiety disorders.
Detailed description
Patients who fulfill the inclusion criteria and are interested in psychotherapy are offered participation in the study to bridge the waiting time for face-to-face psychotherapy. After obtaining informed consent, a pre-treatment assessment is conducted. Then, participants are provided access to velibra, an internet-based cognitive behavioral therapy program which they can work through at their own pace. While velibra is a self-guided program, participants are supported by study personnel during four assessments at four time points: pre-treatment, mid-treatment (after the first three velibra modules), post-treatment and at the one-month follow-up. The investigators expect improvements on the primary as well as the secondary outcomes. Furthermore, the investigators are interested in studying the acceptability of velibra and whether positive changes already become observable after the first three modules, i.e., at the mid-treatment assessment.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Intervention (velibra) | Experimental | Behavioral: VelibraArm consisting of participants who receive velibra, an internet-based cognitive behavioral therapy program. |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Diagnosis of panic disorder with or without agoraphobia, social anxiety disorder, or generalized anxiety disorder
- Knowledge of German that is sufficient for engaging with the treatment and responding to the questionnaires
- Written informed consent
- Internet access
Key exclusion criteria (3 listed)
- Diagnoses of severe mental comorbidities (e.g., schizophrenia, severe major depression, borderline personality disorder)
- Acute suicidality
- Started or changed anxiolytic pharmacotherapy recently (currently or in the past four weeks)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| VelibraVelibra is an internet-based cognitive behavioral therapy program developed by GAIA AG. It consists of six modules which are meant to be completed over a span of 6 weeks. The first module educates participants about anxiety and the treatment program. The second module focuses on cognitive techniques for dealing with anxiety. In the third module, relaxation techniques are practiced. The fourth module encourages the participant to practice non-anxious behaviors. In the fifth module, the central topic is the experience of social situations in non-anxious ways. The sixth and final module consists of a summary and recapitulation of the most important content. | Behavioural | Intervention (velibra) |
Primary outcome
Panic and Agoraphobia Scale (PAS)
Time frame: Baseline (pre-treatment)
The Panic and Agoraphobia Scale (PAS) is a self-report questionnaire used to measure the symptom severity of panic disorder with or without agoraphobia. It is given to study participants diagnosed with panic disorder with or without agoraphobia. Total score values range from 0 to 52, with higher scores indicating a worse outcome.
Panic and Agoraphobia Scale (PAS)
Time frame: During the intervention (mid-treatment)
The Panic and Agoraphobia Scale (PAS) is a self-report questionnaire used to measure the symptom severity of panic disorder with or without agoraphobia. It is given to study participants diagnosed with panic disorder with or without agoraphobia. Total score values range from 0 to 52, with higher scores indicating a worse outcome.
Panic and Agoraphobia Scale (PAS)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
The Panic and Agoraphobia Scale (PAS) is a self-report questionnaire used to measure the symptom severity of panic disorder with or without agoraphobia. It is given to study participants diagnosed with panic disorder with or without agoraphobia. Total score values range from 0 to 52, with higher scores indicating a worse outcome.
Panic and Agoraphobia Scale (PAS)
Time frame: 1-month follow-up
The Panic and Agoraphobia Scale (PAS) is a self-report questionnaire used to measure the symptom severity of panic disorder with or without agoraphobia. It is given to study participants diagnosed with panic disorder with or without agoraphobia. Total score values range from 0 to 52, with higher scores indicating a worse outcome.
Liebowitz Social Anxiety Scale (LSAS)
Time frame: Baseline (pre-treatment)
The Liebowitz Social Anxiety Scale (LSAS) is a self-report questionnaire used to measure the symptom severity of social anxiety disorder. It is given to study participants diagnosed with social anxiety disorder. Total score values range from 0 to 72, with higher scores indicating a worse outcome.
Liebowitz Social Anxiety Scale (LSAS)
Time frame: During the intervention (mid-treatment)
The Liebowitz Social Anxiety Scale (LSAS) is a self-report questionnaire used to measure the symptom severity of social anxiety disorder. It is given to study participants diagnosed with social anxiety disorder. Total score values range from 0 to 72, with higher scores indicating a worse outcome.
Liebowitz Social Anxiety Scale (LSAS)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
The Liebowitz Social Anxiety Scale (LSAS) is a self-report questionnaire used to measure the symptom severity of social anxiety disorder. It is given to study participants diagnosed with social anxiety disorder. Total score values range from 0 to 72, with higher scores indicating a worse outcome.
Liebowitz Social Anxiety Scale (LSAS)
Time frame: 1-month follow-up
The Liebowitz Social Anxiety Scale (LSAS) is a self-report questionnaire used to measure the symptom severity of social anxiety disorder. It is given to study participants diagnosed with social anxiety disorder. Total score values range from 0 to 72, with higher scores indicating a worse outcome.
Penn State Worry Questionnaire (PSWQ)
Time frame: Baseline (pre-treatment)
The Penn State Worry Questionnaire (PSWQ) is a self-report questionnaire used to measure the symptom severity of generalized anxiety disorder It is given to study participants diagnosed with generalized anxiety disorder. Total score values range from 16 to 80, with higher scores indicating a worse outcome.
Penn State Worry Questionnaire (PSWQ)
Time frame: During the intervention (mid-treatment)
The Penn State Worry Questionnaire (PSWQ) is a self-report questionnaire used to measure the symptom severity of generalized anxiety disorder It is given to study participants diagnosed with generalized anxiety disorder. Total score values range from 16 to 80, with higher scores indicating a worse outcome.
Penn State Worry Questionnaire (PSWQ)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
The Penn State Worry Questionnaire (PSWQ) is a self-report questionnaire used to measure the symptom severity of generalized anxiety disorder It is given to study participants diagnosed with generalized anxiety disorder. Total score values range from 16 to 80, with higher scores indicating a worse outcome.
Penn State Worry Questionnaire (PSWQ)
Time frame: 1-month follow-up
The Penn State Worry Questionnaire (PSWQ) is a self-report questionnaire used to measure the symptom severity of generalized anxiety disorder It is given to study participants diagnosed with generalized anxiety disorder. Total score values range from 16 to 80, with higher scores indicating a worse outcome.
28 secondary outcomes
Beck Anxiety Inventory (BAI)
Time frame: Baseline (pre-treatment)
Beck Anxiety Inventory (BAI)
Time frame: During the intervention (mid-treatment)
Beck Anxiety Inventory (BAI)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
Beck Anxiety Inventory (BAI)
Time frame: 1-month follow-up
Beck Depression Inventory-II (BDI-II)
Time frame: Baseline (pre-treatment)
Beck Depression Inventory-II (BDI-II)
Time frame: During the intervention (mid-treatment)
Beck Depression Inventory-II (BDI-II)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
Beck Depression Inventory-II (BDI-II)
Time frame: 1-month follow-up
Anxiety Sensitivity Index (ASI)
Time frame: Baseline (pre-treatment)
Anxiety Sensitivity Index (ASI)
Time frame: During the intervention (mid-treatment)
Anxiety Sensitivity Index (ASI)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
Anxiety Sensitivity Index (ASI)
Time frame: 1-month follow-up
ICD-10-Symptom-Rating (ISR)
Time frame: Baseline (pre-treatment)
ICD-10-Symptom-Rating (ISR)
Time frame: During the intervention (mid-treatment)
ICD-10-Symptom-Rating (ISR)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
ICD-10-Symptom-Rating (ISR)
Time frame: 1-month follow-up
Short-Form Health Survey (SF-12)
Time frame: Baseline (pre-treatment)
Short-Form Health Survey (SF-12)
Time frame: During the intervention (mid-treatment)
Short-Form Health Survey (SF-12)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
Short-Form Health Survey (SF-12)
Time frame: 1-month follow-up
General Self--Efficacy Scale (GES)
Time frame: Baseline (pre-treatment)
General Self--Efficacy Scale (GES)
Time frame: During the intervention (mid-treatment)
General Self--Efficacy Scale (GES)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
General Self--Efficacy Scale (GES)
Time frame: 1-month follow-up
Internal, Powerful Others, and Chance Questionnaire (IPC)
Time frame: Baseline (pre-treatment)
Internal, Powerful Others, and Chance Questionnaire (IPC)
Time frame: During the intervention (mid-treatment)
Internal, Powerful Others, and Chance Questionnaire (IPC)
Time frame: Immediately after / as soon as possible after the intervention (post-treatment)
Internal, Powerful Others, and Chance Questionnaire (IPC)
Time frame: 1-month follow-up
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 7 May 2026.
Related trials for Panic Disorder With Agoraphobia
Not yet recruiting
A Clinical Trial to Evaluate the Efficacy and Safety of Meltz, a Digital Therapeutic Device, for Improving Panic Symptoms in Patients With Panic Disorder
Panic Disorder, Agoraphobia
Active, not recruiting
Evaluation of Family-Based Behavioral Treatments for Youth With Anxiety and Obsessive-Compulsive Disorder
Obsessive-Compulsive Disorder in Children, Anxiety Disorder of Childhood
Recruiting
Qigong and Multicomponent Exercise in Panic Disorder
Panic Disorder, Panic Disorder (With or Without Agoraphobia)
Recruiting
Anxiety Skills Study
Anxiety, Anxiety Acute
Active, not recruiting
Comparative Effectiveness of Internet-based Versus Parent-Coached Cognitive-Behavioral Therapy For Children and Adolescents With Anxiety and OCD
Obsessive Compulsive Disorder (OCD), Anxiety Disorder of Childhood or Adolescence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Lena Pyrkosch, Dipl.-Psych. principal investigator
Department of Psychiatry and Psychotherapy, Charité Campus Mitte - Universitätsmedizin Berlin
Anna Wehrheim, M.Sc.-Psych. principal investigator
Department of Psychiatry and Psychotherapy, Charité Campus Mitte - Universitätsmedizin Berlin
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Velibra in people with Panic Disorder With Agoraphobia and Panic Disorder Without Agoraphobia, run by Charite University, Berlin, Germany at 1 site in Germany.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 7 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Germany. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Anna Wehrheim, M.Sc.-Psych. (+49 30 450 517 017, anna.wehrheim@charite.de), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Panic and Agoraphobia Scale (PAS) (time frame: Baseline (pre-treatment)). The study lists 12 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 7 May 2026.